Blog

RSS Feed
Posted by Michael Wonder on 19 Apr 2022

Supply related data in manufacturer dossiers: things are not going smoothly yet

19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science.  ...

Read more →
Posted by Michael Wonder on 26 Feb 2022

COVID-19 vaccines: individual patient data should be submitted to the European Medicines Agency

24 February 2022 - An interesting letter to the Editor of the BMJ from the Head of Drug Assessment at ...

Read more →
Posted by Michael Wonder on 16 Mar 2020

Regulatory and health technology assessment advice on post‐licensing and post‐launch evidence generation is a foundation for lifecycle data collection for medicines

11 March 2020 - The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially ...

Read more →
Posted by Michael Wonder on 25 Jan 2020

Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs

24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...

Read more →
Posted by Michael Wonder on 05 Jan 2016

IQWIG Autumn Symposium 2015: presentations now online

5 January 2016 - Real world data: a gain for benefit assessments? This question was the focus of the Autumn Symposium ...

Read more →